Deazapurines and uses thereof

Details Deazapurines and uses thereof Deazapurines and uses thereof

2011-01-11

2011-01-11

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S303000, C546S118000, C544S405000

Reexamination Certificate

active

07868002

ABSTRACT:
As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I),and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

REFERENCES:
patent: 3891660 (1975-06-01), Denzel et al.
patent: 4891374 (1990-01-01), Thorwart et al.
patent: 5342832 (1994-08-01), Siren
patent: 5360794 (1994-11-01), Arora
patent: 5486525 (1996-01-01), Summers et al.
patent: 5492915 (1996-02-01), Dereu et al.
patent: 5506238 (1996-04-01), Miyake et al.
patent: 5565452 (1996-10-01), Arndts et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
patent: 5654305 (1997-08-01), Shepard et al.
patent: 5656654 (1997-08-01), Buzzetti et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5981536 (1999-11-01), Mullner et al.
patent: 6143743 (2000-11-01), Wilde et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 6521654 (2003-02-01), Wehner et al.
patent: 6599741 (2003-07-01), Hecker et al.
patent: 6831065 (2004-12-01), May et al.
patent: RE39464 (2007-01-01), Cook et al.
patent: 7314936 (2008-01-01), Daun et al.
patent: 2004/0186127 (2004-09-01), Daun et al.
patent: 2006/0194833 (2006-08-01), Chase et al.
patent: 0434405 (1990-12-01), None
patent: 0434405 (1991-06-01), None
patent: 0 945 422 (1999-09-01), None
patent: 0 945 443 (1999-09-01), None
patent: 0 399 731 (2001-07-01), None
patent: 1 256 582 (2002-11-01), None
patent: WO 99/01454 (1999-01-01), None
patent: WO 99/65909 (1999-12-01), None
patent: WO 00 76505 (2000-12-01), None
patent: WO 01/00610 (2001-01-01), None
patent: WO 01/30774 (2001-05-01), None
patent: WO 01/30778 (2001-05-01), None
patent: WO 01/30778 (2001-05-01), None
patent: WO 01/58900 (2001-08-01), None
Csaszar et al., European journal of pharmacology, (Feb. 23, 2001), vol. 414, No. 1, pp. 9-22. Ref: 100.
Abrahamsen, et al., “Cytokines and Bone Loss in a 5-Year Longitudinal Study—Hormone Replacement Therapy Suppresses Serum Soluble Interlukin-6 Receptor and Increases Interlukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study”Journal of Bone and Mineral Research15: 1545-1554, 2000.
Azuma, et al., “Tumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts”Journal of Biological Chemistry275(7): 4858-4864, 2000.
Cain, et al., “p-38 MAPK Inhibition Decreases TNF-α Production and Enhances Postischemic Human Myocardial Function”Journal of Surgical Research83: 7-12, 1999.
Koyano, et al., “Effects of FR167653 on Ischenia-reperfusion Injury: Evaluation Through Preservation and Transplantation in Canine Hearts”J. Heart Lung Transplant17: 1247-54, 1998.
Souza, et al., “Effects of Inhibition of PDE4 and TNF-α On Local And Remote Injuries Following Ischaemia And Reperfusion Injury”British Journal of Pharmacology134: 985-994, 2001.
Abrahamsen, et al., “Cytokines and Bone Loss in a 5-Year Longitudinal Study—Hormone Replacement Therapy Suppresses Serum Soluble Interlukin-6 Receptor and Increases Interleukin-1-Receptor Antagonist: The Danish Osteoporosis Prevention Study”Journal of Bone and Mineral Research: 15 (8): 1545-1554, 2000.
Cain, et al., “p-38 MAPK Inhibition Decreases TNF-α Production and Enhances Postischemic Human Myocardial Function”Journal of Surgical Research83 (1): 7-12, 1999.
Koyano, et al., “Effects of FR167653 on Ischemia-reperfusion Injury: Evaluation Through Preservation and Transplantation in Canine Hearts”J. Heart Lung Transplant17 (12): 1247-54, 1998.
Souza, et al., “Effects of Inhibition of PDE4 and TNF-α On Local And Remote Injuries Following Ischaemia And Reperfusion Injury”British Journal of Pharmacology134 (5): 985-994, 2001.
International Search Report for Related International Application No: PCT/US2004/000293.
Yusuf-Makagiansar et al. “Inhibition of LFA-1/ICAN-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases”,Med. Res. Rev.22(2):146-167 (2002).
Norton et al. “Expression of adhesion molecules in human intestinal graft-versus-host disease”,Clin. Exp. Immunol. 87:231-236 (1992).
Brodt et al. “Liver Endothelial E-Selectin Mediates Carcinoma Cell Adhesion and Promotes Liver Metastasis”,Int. J. Cancer71:612-619 (1997).
Finzel et al. “ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells”,Clin. amd Exp. Metastasis21:185-189 (2004).
Rosette et al. “Role of ICAM1 in invasion of human breast cancer cells”,Carcinogenesis26(5):943-950 (2005).
Tak et al. “NF-κB: a key role in inflammatory diseases”,J. Clin. Investigation107(1):7-11 (2001).
Smith CH, et al. Adhesion molecules in allergic inflammation. American Review of Respiratory Disease. 1993. vol. 148(Supplement), pp. S75-S78.
Nikolic-Paterson DJ, et al. Adhesion molecules in glomerulonephritis. Springer Semin Immunopathol. 1994. vol. 15, p. 3-22.
Parekh RB and Edge CJ. Selectins—glycoprotein targets for therapeutic intervention in inflammation. Trends in Biotechnology. Sep. 1994. vol. 12, pp. 339-345.
Andres G, et al. Suppression of experimental glomerulonephritis by interference with T- or B-Cell Activation signals or adhesion molecules. Advances in Nephrology from the Necker Hospital. 1995. vol. 24, pp. 91-105.
Barker, Jnwn. Adhesion of molecules in cutaneous inflammation. Cell Adhesion and Human Disease. Ciba Foundation Symposium 189. John Wiley & Sons. 1995. pp. 91-106.
Baroody FM, et al. Implicating adhesion molecules in nasal allergic inflammation. Eur. Arch. Otorhinolaryngol. 1995. vol. 252(Supplement.1), pp. S50-S58.
Archelos JJ and Hartung H-P. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Molecular Medicine Today. Jul. 1997. pp. 310-321.
Losy J, et al. Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions. Journal of Neuroimmunology. 1999. vol. 99, pp. 169-172.
Takasaki Y, et al. The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patiens(sic): implication for immunotherapy. Internal Medicine. Feb. 1999. vol. 38, No. 2, pp. 175-177.
Ribau Jco, et al. Endothelial adhesion molecule expression is enhanced in the aorta and internal mammary artery of diabetic patients. Journal of Surgical Research. Aug. 1999. vol. 85, No. 2, pp. 225-233.
Yeung M M-W, et al. Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-γδ expression. Gut. 2000. vol. 47, pp. 215-227.
Hokari R, et al. Involvement of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in the pathogenesis of granulomatous colitis in rats. Clinical and Experimental Immunology. 2001. vol. 126, pp. 259-265.
Greten FR, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. Aug. 6, 2004, vol. 118, pp. 285-296.
Nakanishi C and Toi M. Nuclear factor-κβ inhibitors as sensitizers to anticancer drugs. Nature Reviews. Apr. 2005, vol. 5, pp. 297-309.
Dunoyer-Geindre S et al. Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome. Haematologica. 2008. vol. 93, Issue 4, pp. 635-636.
Krenitsky et al. “Imidazo[4,5-c]pyridines (3-Deazapurines) and Their Nucleosides as Immunosuppressive and Antiinflammatory Agents”,J. Med. Chem.29:138-143 (1986).
International Search Report for PCT/US03/00366.

Affiliated with

Also associated with

Rating

Deazapurines and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Deazapurines and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Deazapurines and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2677286